235 related articles for article (PubMed ID: 11928940)
1. Acute effects of nitric oxide synthase inhibition on systemic, hepatic, and renal hemodynamics in patients with cirrhosis and ascites.
Spahr L; Martin PY; Giostra E; Niederberger M; Lang U; Capponi A; Hadengue A
J Investig Med; 2002 Mar; 50(2):116-24. PubMed ID: 11928940
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis.
La Villa G; Barletta G; Pantaleo P; Del Bene R; Vizzutti F; Vecchiarino S; Masini E; Perfetto F; Tarquini R; Gentilini P; Laffi G
Hepatology; 2001 Jul; 34(1):19-27. PubMed ID: 11431729
[TBL] [Abstract][Full Text] [Related]
3. Changes in renal and systemic hemodynamics after NO-synthase inhibition in males with family history of hypertension.
Berger ED; Bader BD; Rüb N; Rauscher MA; Rebenschütz I; Gaber OC; Enderle MD; Risler T; Erley CM
Kidney Blood Press Res; 2002; 25(1):42-9. PubMed ID: 11834876
[TBL] [Abstract][Full Text] [Related]
4. Enhanced sodium retention after acute nitric oxide blockade in mildly sodium loaded patients with essential hypertension.
Bech JN; Nielsen EH; Pedersen RS; Svendsen KB; Pedersen EB
Am J Hypertens; 2007 Mar; 20(3):287-95. PubMed ID: 17324742
[TBL] [Abstract][Full Text] [Related]
5. Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition.
Millar CG; Thiemermann C
Br J Pharmacol; 1997 Aug; 121(8):1824-30. PubMed ID: 9283724
[TBL] [Abstract][Full Text] [Related]
6. The renal and systemic hemodynamic effects of a nitric oxide-synthase inhibitor are reversed by a selective endothelin(a) receptor antagonist in men.
Schmidt A; Bayerle-Eder M; Pleiner H; Zeisner C; Wolzt M; Mayer G; Schmetterer L
Nitric Oxide; 2001 Aug; 5(4):370-6. PubMed ID: 11485375
[TBL] [Abstract][Full Text] [Related]
7. Renal effects of NO-inhibition in patients with cirrhosis vs. healthy controls: a randomized placebo-controlled crossover study.
Bech JN; Aagaard NK; Pedersen RS; Sorensen TB; Vilstrup H; Pedersen EB
Liver Int; 2014 Feb; 34(2):211-9. PubMed ID: 23809512
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites.
Thiesson HC; Skøtt O; Jespersen B; Schaffalitzky de Muckadell OB
Am J Gastroenterol; 2003 Jan; 98(1):180-6. PubMed ID: 12526955
[TBL] [Abstract][Full Text] [Related]
9. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF.
Tilton RG; Chang KC; LeJeune WS; Stephan CC; Brock TA; Williamson JR
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):689-96. PubMed ID: 10067972
[TBL] [Abstract][Full Text] [Related]
10. Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension.
Wang JJ; Gao GW; Gao RZ; Liu CA; Ding X; Yao ZX
World J Gastroenterol; 2004 Mar; 10(5):689-93. PubMed ID: 14991939
[TBL] [Abstract][Full Text] [Related]
11. Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: reversal by L-arginine.
Wolzt M; Schmetterer L; Ferber W; Artner E; Mensik C; Eichler HG; Krejcy K
Am J Physiol; 1997 Feb; 272(2 Pt 2):F178-82. PubMed ID: 9124393
[TBL] [Abstract][Full Text] [Related]
12. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C
J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
[TBL] [Abstract][Full Text] [Related]
13. Nifedipine attenuates systemic and renal vasoconstriction during nitric oxide inhibition in humans.
Dijkhorst-Oei LT; Rabelink TJ; Boer P; Koomans HA
Hypertension; 1997 May; 29(5):1192-8. PubMed ID: 9149686
[TBL] [Abstract][Full Text] [Related]
14. Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects.
Jacobi J; Schneider MP; John S; Schmieder RE
J Hypertens; 2002 Mar; 20(3):525-30. PubMed ID: 11875321
[TBL] [Abstract][Full Text] [Related]
15. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Christos P; Paraskevi K; Konstantinos P; Katsaraki A; Tsianos EV
Dig Dis Sci; 2005 Oct; 50(10):1771-7. PubMed ID: 16187171
[TBL] [Abstract][Full Text] [Related]
16. Effect of nitric oxide inhibition on blood pressure and renal sodium handling: a dose-response study in healthy man.
Larsen T; Mose FH; Bech JN; Pedersen EB
Clin Exp Hypertens; 2012; 34(8):567-74. PubMed ID: 22559218
[TBL] [Abstract][Full Text] [Related]
17. The ocular hemodynamic response to nitric oxide synthase inhibition is unaltered in patients with early type I diabetes.
Dorner GT; Garhöfer G; Selenko N; Fasching P; Bayerle-Eder M; Schmetterer L; Wolzt M
Graefes Arch Clin Exp Ophthalmol; 2003 Aug; 241(8):619-24. PubMed ID: 12836035
[TBL] [Abstract][Full Text] [Related]
18. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide.
Siragy HM; Jaffa AA; Margolius HS
Hypertension; 1997 Mar; 29(3):757-62. PubMed ID: 9052892
[TBL] [Abstract][Full Text] [Related]
19. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
Muskiet MH; Tonneijck L; Smits MM; Kramer MH; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2016 Feb; 18(2):178-85. PubMed ID: 26636423
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and sympathetic responses to human atrial natriuretic peptide infusion in patients with cirrhosis.
Brenard R; Moreau R; Pussard E; Champigneulle B; Gaudin C; Hadengue A; Braillon A; Lebrec D
J Hepatol; 1992 Mar; 14(2-3):347-56. PubMed ID: 1386858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
